AlphaQuest LLC Purchases 9,987 Shares of Henry Schein, Inc. $HSIC

AlphaQuest LLC boosted its position in Henry Schein, Inc. (NASDAQ:HSIC) by 91.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,861 shares of the company’s stock after acquiring an additional 9,987 shares during the quarter. AlphaQuest LLC’s holdings in Henry Schein were worth $1,385,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HSIC. AQR Capital Management LLC grew its position in Henry Schein by 47.3% in the first quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after acquiring an additional 9,756 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Henry Schein by 1.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock worth $1,155,000 after acquiring an additional 229 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Henry Schein in the 1st quarter valued at approximately $676,000. Truist Financial Corp grew its holdings in shares of Henry Schein by 21.1% during the 2nd quarter. Truist Financial Corp now owns 5,365 shares of the company’s stock valued at $392,000 after purchasing an additional 934 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Henry Schein by 4.1% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,526 shares of the company’s stock worth $1,134,000 after purchasing an additional 610 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Trading Up 1.5%

HSIC opened at $75.48 on Friday. Henry Schein, Inc. has a twelve month low of $60.56 and a twelve month high of $82.49. The company has a fifty day moving average of $76.29 and a 200-day moving average of $70.79. The stock has a market cap of $8.89 billion, a PE ratio of 23.89, a price-to-earnings-growth ratio of 2.21 and a beta of 0.88. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.11. The business had revenue of $3.34 billion for the quarter, compared to analysts’ expectations of $3.28 billion. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. On average, sell-side analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on HSIC. Mizuho set a $81.00 target price on shares of Henry Schein and gave the company a “neutral” rating in a research report on Tuesday, January 20th. Wells Fargo & Company raised their price objective on Henry Schein from $70.00 to $76.00 and gave the company an “equal weight” rating in a report on Wednesday, November 5th. Evercore ISI boosted their price objective on Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. JPMorgan Chase & Co. increased their target price on Henry Schein from $76.00 to $78.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Five investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $76.42.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.